GlassScriptPhysician profile
Vincent Vargas
NPI 1629234851
$16,314.44
in general payments reported to CMS, 2019-2025
37 companies · $4,135 in 2025
The $4,135 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2020: $18.95 · 2021: $948 · 2022: $2,176 · 2023: $3,742 · 2024: $5,145 · 2025: $4,135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $10.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,010.72 |
| Education | $10.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $5,158.08 | 2021-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $2,977.17 | 2021-2025 | Biktarvy |
| Abbvie INC. | $1,926.46 | 2021-2025 | Vraylar, Viberzi, Linzess |
| Novo Nordisk INC | $934.51 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $865.70 | 2021-2025 | Pifeltro, Delstrigo, Dificid |
| Emd Serono, INC. | $520.95 | 2021-2025 | Serostim |
| Amgen INC. | $401.04 | 2021-2025 | Repatha, Otezla, Repatha |
| Axsome Therapeutics, INC. | $378.95 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $277.83 | 2023-2025 | Spravato, Symtuza |
| Theratechnologies INC. | $277.44 | 2021-2025 | Trogarzo, Egrifta |
| Napo Pharmaceuticals INC | $269.65 | 2021-2025 | Mytesi |
| Lilly USA, LLC | $268.74 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Otsuka America Pharmaceutical, INC. | $261.11 | 2022-2025 | Rexulti, Abilify Maintena |
| Glaxosmithkline, LLC. | $216.28 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $213.17 | 2024-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $177.96 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $116.03 | 2025 | Farxiga, Breztri |
| Exact Sciences Corporation | $111.70 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Antares Pharma, INC. | $107.23 | 2022 | |
| Janssen Biotech, INC. | $105.23 | 2021-2023 | Symtuza |
| Takeda Pharmaceuticals U.S.A., INC. | $100.20 | 2021-2025 | Trintellix |
| Janssen Products, LP | $99.95 | 2021 | |
| Corcept Therapeutics | $85.96 | 2024-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.35 | 2023-2025 | Jardiance |
| Idorsia Pharmaceuticals US INC | $51.24 | 2022-2023 | Quviviq |
| Lundbeck LLC | $47.30 | 2024 | Rexulti |
| Halozyme INC | $43.91 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.37 | 2023-2025 | Caplyta |
| Abbott Laboratories | $39.06 | 2024-2025 | Freestyle Libre 3 |
| Vivus LLC | $34.17 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.19 | 2021-2024 | Xifaxan |
| Aimmune Therapeutics, INC. | $25.92 | 2025 | Zenpep |
| Inspire Medical Systems, INC. | $25.00 | 2024 | Inspire |
| Supernus Pharmaceuticals, INC. | $21.98 | 2024 | Xyosted, Tlando, Qelbree |
| Corium, LLC | $20.39 | 2023 | Azstarys |
| Azurity Pharmaceuticals, INC. | $15.85 | 2024 | |
| Medline Industries LP | $14.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Vargas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.